What were Cipla Ltd's latest quarterly results?
Cipla Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -57.2%
- Revenue Growth YoY: 0.0%
- Operating Margin: 18.0%
Cipla Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 21.1. ROE: 17.8%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Cipla Ltd's latest quarterly results (Dec 2025) show
Cipla Ltd's current PE ratio is 21.1x.
Cipla Ltd's price-to-book ratio is 3.0x.
Cipla Ltd's fundamental strength based on key financial ratios
Cipla Ltd has a debt-to-equity ratio of N/A.
Cipla Ltd's return ratios over recent years
Cipla Ltd's operating cash flow is positive (FY2025).
Cipla Ltd's current dividend yield is 1.05%.
Cipla Ltd's shareholding pattern (Dec 2025)
Cipla Ltd's promoter holding has remained stable recently.
Cipla Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Cipla Ltd may be worth studying
Cipla Ltd investment thesis summary:
Cipla Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.